Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Hughes-Davies, Luke"'
Autor:
Earl H; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.; Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; NIHR Cambridge Biomedical Research Centre, Cambridge, UK., Hiller L; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., Vallier AL; Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Loi S; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., McAdam K; Department of Oncology, North West Anglia NHS Foundation Trust, Peterborough City Hospital, Peterborough, UK.; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Hughes-Davies L; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Rea D; Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Howe D; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., Raynes K; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., Higgins HB; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., Wilcox M; Independent Cancer Patients' Voice, London, UK., Plummer C; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.; Department of Cardiology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Mahler-Araujo B; Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Metabolic Research Laboratories, University of Cambridge, Cambridge, UK., Provenzano E; NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Chhabra A; Pharmacy, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK., Gasson S; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., Balmer C; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., Abraham JE; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.; Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; NIHR Cambridge Biomedical Research Centre, Cambridge, UK., Caldas C; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.; Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; NIHR Cambridge Biomedical Research Centre, Cambridge, UK.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Hall P; Edinburgh University Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK., Shinkins B; Academic Unit of Health Economics, University of Leeds, Leeds, UK., McCabe C; Institute of Health Economics, Edmonton, AB, Canada., Hulme C; Academic Unit of Health Economics, University of Leeds, Leeds, UK.; Health Economics Group, University of Exeter Medical School, Exeter, UK., Miles D; Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK., Wardley AM; NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK., Cameron DA; Edinburgh University Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK., Dunn JA; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
Publikováno v:
Health technology assessment (Winchester, England) [Health Technol Assess] 2020 Aug; Vol. 24 (40), pp. 1-190.
Autor:
Earl HM; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge Breast Cancer Research Unit, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK; National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK. Electronic address: hme22@cam.ac.uk., Hiller L; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., Vallier AL; Cambridge Clinical Trials Unit-Cancer Theme, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK., Loi S; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., McAdam K; Department of Oncology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK; Department of Oncology, North West Anglia NHS Foundation Trust, Peterborough City Hospital, Peterborough, UK., Hughes-Davies L; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Department of Oncology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK., Harnett AN; Department of Oncology, James Paget University Hospital, Norfolk, UK; Department of Oncology, Norfolk & Norwich University Hospital, Norwich, UK., Ah-See ML; Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK., Simcock R; Sussex Cancer Centre, Brighton and Sussex University Hospitals NHS, Brighton, UK., Rea D; Cancer Research UK Clinical Trials Unit and Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Raj S; Department of Oncology, Southampton University Hospital NHS Foundation Trust, Southampton, UK., Woodings P; Department of Oncology, Royal Derby Hospital, Derby, UK., Harries M; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Howe D; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., Raynes K; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., Higgins HB; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., Wilcox M; Independent Cancer Patients Voice, London, UK., Plummer C; Department of Cardiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Freeman Hospital, Newcastle upon Tyne, UK., Mansi J; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Gounaris I; Oncology Global Drug Development, Novartis, Basel, Switzerland., Mahler-Araujo B; Metabolic Research Laboratories, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Department of Histopathology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK., Provenzano E; Department of Histopathology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK; National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK., Chhabra A; Pharmacy, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK., Abraham JE; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge Breast Cancer Research Unit, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK; National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK., Caldas C; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge Breast Cancer Research Unit, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK; National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK; Cancer Research UK Cambridge Institute, University of Cambridge Li Ka Shing Centre, Cambridge, UK., Hall PS; Cancer Edinburgh Research Centre, The Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK., McCabe C; Institute of Health Economics, Edmonton, Canada., Hulme C; Academic Unit of Health Economics, University of Leeds, Leeds, UK; Health Economics Group, Institute of Health Research, University of Exeter Medical School, Exeter, UK., Miles D; Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK., Wardley AM; Research & Development, The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, ManchesterAcademic Health Science Centre, University of Manchester, Manchester, UK., Cameron DA; Cancer Edinburgh Research Centre, The Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK., Dunn JA; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
Publikováno v:
Lancet (London, England) [Lancet] 2019 Jun 29; Vol. 393 (10191), pp. 2599-2612. Date of Electronic Publication: 2019 Jun 06.
Autor:
Earl, Helena M, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna, Raynes, Kerry, Higgins, Helen B, Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis, Mahler-Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Abraham, Jean E, Caldas, Carlos, Hall, Peter S, McCabe, Christopher, Hulme, Claire, Miles, David, Wardley, Andrew M, Cameron, David A, Dunn, Janet A, PERSEPHONE Steering Committee And Trial Investigators
BACKGROUND: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d38dc3a61d6f5a1d3ff191f5371eef15